Arcus Biosciences (RCUS) Stock Forecast & Price Target

Compare

535 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RCUS Analyst Ratings

Strong Buy

9 Buy

2 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Arcus

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RCUS Stock 12 Month Forecast

Average Price Target

$27.78

▲(26.39% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Arcus Biosciences in the last 3 months. The average price target is $27.78 with a high forecast of $44.00 and a low forecast of $14.00. The average price target represents a 26.39% change from the last price of $21.98.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","45":"$45","15.75":"$15.75","25.5":"$25.5","35.25":"$35.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$44.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,15.75,25.5,35.25,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.1,27.47692307692308,28.853846153846156,30.230769230769234,31.60769230769231,32.98461538461539,34.36153846153846,35.738461538461536,37.11538461538461,38.49230769230769,39.86923076923077,41.246153846153845,42.62307692307692,{"y":44,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.1,26.22923076923077,26.35846153846154,26.48769230769231,26.61692307692308,26.74615384615385,26.87538461538462,27.004615384615384,27.133846153846154,27.263076923076923,27.392307692307693,27.521538461538462,27.65076923076923,{"y":27.78,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.1,25.169230769230772,24.23846153846154,23.30769230769231,22.376923076923077,21.446153846153848,20.515384615384615,19.584615384615386,18.653846153846153,17.723076923076924,16.792307692307695,15.861538461538462,14.930769230769231,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.89,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$44.00

Average Price Target$27.78

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yigal Nochomovitz

Citi

$56→$44

Buy

100.18%

Upside

Reiterated

12/15/25

Arcus Biosciences price target lowered to $44 from $56 at CitiArcus Biosciences price target lowered to $44 from $56 at Citi

Asthika Goonewardene

Truist Financial

$30

Buy

36.49%

Upside

Reiterated

12/15/25

Arcus Biosciences: Strategic Shift to Casdatifan with Strong Financial Position and Buy Rating

Jason Zemansky

Bank of America Securities

$26

Hold

18.29%

Upside

Reiterated

12/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioCryst (NASDAQ: BCRX), Arcus Biosciences (NYSE: RCUS) and Amicus (NASDAQ: FOLD)

Eva Fortea Verdejo

Wells Fargo

$29→$30

Buy

36.49%

Upside

Assigned

12/12/25

Wells Fargo Remains a Buy on Arcus Biosciences (RCUS)

Emily Bodnar

H.C. Wainwright

$28→$32

Buy

45.59%

Upside

Reiterated

12/12/25

Arcus Biosciences: Strategic Focus and Financial Positioning Drive Buy Rating

Terence Flynn

Morgan Stanley

$23

Buy

4.64%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: MiMedx Group (NASDAQ: MDXG), TransMedics Group (NASDAQ: TMDX) and Arcus Biosciences (NYSE: RCUS)

Salveen Richter

Goldman Sachs

$14→$16

Hold

-27.21%

Downside

Reiterated

10/30/25

Goldman Sachs Sticks to Its Hold Rating for Arcus Biosciences (RCUS)

Robert Driscoll

Wedbush

$33→$35

Buy

59.24%

Upside

Reiterated

10/29/25

Wedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Peter Lawson

Barclays

$14

Buy

-36.31%

Downside

Reiterated

10/28/25

Arcus Biosciences (RCUS) Receives a Buy from Barclays

Umer Raffat

Evercore ISI

Buy

―

Reiterated

10/08/25

Evercore ISI Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Li Watsek

Cantor Fitzgerald

Buy

―

Reiterated

10/08/25

Arcus Biosciences (RCUS) Gets a Buy from Cantor Fitzgerald

Salim Syed

Mizuho Securities

$42→$45

Buy

104.73%

Upside

Reiterated

08/18/25

Mizuho Securities Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Daina Graybosch

Leerink Partners

$46→$52

Buy

136.58%

Upside

Reiterated

08/07/25

Leerink Partners Sticks to Their Buy Rating for Arcus Biosciences (RCUS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yigal Nochomovitz

Citi

$56→$44

Buy

100.18%

Upside

Reiterated

12/15/25

Arcus Biosciences price target lowered to $44 from $56 at CitiArcus Biosciences price target lowered to $44 from $56 at Citi

Asthika Goonewardene

Truist Financial

$30

Buy

36.49%

Upside

Reiterated

12/15/25

Arcus Biosciences: Strategic Shift to Casdatifan with Strong Financial Position and Buy Rating

Jason Zemansky

Bank of America Securities

$26

Hold

18.29%

Upside

Reiterated

12/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioCryst (NASDAQ: BCRX), Arcus Biosciences (NYSE: RCUS) and Amicus (NASDAQ: FOLD)

Eva Fortea Verdejo

Wells Fargo

$29→$30

Buy

36.49%

Upside

Assigned

12/12/25

Wells Fargo Remains a Buy on Arcus Biosciences (RCUS)

Emily Bodnar

H.C. Wainwright

$28→$32

Buy

45.59%

Upside

Reiterated

12/12/25

Arcus Biosciences: Strategic Focus and Financial Positioning Drive Buy Rating

Terence Flynn

Morgan Stanley

$23

Buy

4.64%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: MiMedx Group (NASDAQ: MDXG), TransMedics Group (NASDAQ: TMDX) and Arcus Biosciences (NYSE: RCUS)

Salveen Richter

Goldman Sachs

$14→$16

Hold

-27.21%

Downside

Reiterated

10/30/25

Goldman Sachs Sticks to Its Hold Rating for Arcus Biosciences (RCUS)

Robert Driscoll

Wedbush

$33→$35

Buy

59.24%

Upside

Reiterated

10/29/25

Wedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Peter Lawson

Barclays

$14

Buy

-36.31%

Downside

Reiterated

10/28/25

Arcus Biosciences (RCUS) Receives a Buy from Barclays

Umer Raffat

Evercore ISI

Buy

―

Reiterated

10/08/25

Evercore ISI Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Li Watsek

Cantor Fitzgerald

Buy

―

Reiterated

10/08/25

Arcus Biosciences (RCUS) Gets a Buy from Cantor Fitzgerald

Salim Syed

Mizuho Securities

$42→$45

Buy

104.73%

Upside

Reiterated

08/18/25

Mizuho Securities Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Daina Graybosch

Leerink Partners

$46→$52

Buy

136.58%

Upside

Reiterated

08/07/25

Leerink Partners Sticks to Their Buy Rating for Arcus Biosciences (RCUS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcus Biosciences

1 Month

xxx

Success Rate

8/14 ratings generated profit

Average Return

+5.52%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +5.52% per trade.

3 Months

xxx

Success Rate

12/22 ratings generated profit

Average Return

+7.73%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +7.73% per trade.

1 Year

Peter LawsonBarclays

Success Rate

15/27 ratings generated profit

Average Return

+32.73%

reiterated a buy rating 2 months ago

Copying Peter Lawson's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +32.73% per trade.

2 Years

xxx

Success Rate

19/27 ratings generated profit

Average Return

+43.59%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.37% of your transactions generating a profit, with an average return of +43.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RCUS Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RCUS has received 23 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. RCUS average Analyst price target in the past 3 months is 27.78.

Each month's total comprises the sum of three months' worth of ratings.

RCUS Financial Forecast

RCUS Earnings Forecast

Next quarter’s earnings estimate for RCUS is -$1.13 with a range of -$1.24 to -$1.00. The previous quarter’s EPS was -$1.27. RCUS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year RCUS has Performed in-line its overall industry.

RCUS Sales Forecast

Next quarter’s sales forecast for RCUS is $35.60M with a range of $16.00M to $121.90M. The previous quarter’s sales results were $26.00M. RCUS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year RCUS has Performed in-line its overall industry.

RCUS Stock Forecast FAQ

What is RCUS’s average 12-month price target, according to analysts?

Based on analyst ratings, Arcus Biosciences Inc’s 12-month average price target is 27.78.

What is RCUS’s upside potential, based on the analysts’ average price target?

Arcus Biosciences Inc has 26.39% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RCUS a Buy, Sell or Hold?

Arcus Biosciences Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 2 hold ratings and 0 sell ratings.

What is Arcus Biosciences Inc’s price target?

The average price target for Arcus Biosciences Inc is 27.78. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $44.00 ,the lowest forecast is $14.00. The average price target represents 26.39% Increase from the current price of $21.98.

What do analysts say about Arcus Biosciences Inc?

Arcus Biosciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of RCUS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Arcus Biosciences (RCUS) Stock Forecast & Price Target

RCUS Analyst Ratings

RCUS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arcus Biosciences

RCUS Analyst Recommendation Trends

RCUS Financial Forecast

RCUS Earnings Forecast

RCUS Sales Forecast

RCUS Stock Forecast FAQ

Detailed List of Analyst Forecasts